Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
The purpose of this study is to determine the effectiveness of enzalutamide, versus a
conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone
releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation
therapy (ADT) for newly diagnosed metastatic prostate cancer.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society